• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Protagonist Therapeutics Inc (NQ: PTGX )

    44.92 +0.33 (+0.74%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 10, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Protagonist Therapeutics Inc

    < Previous 1 2 3 4 5 6 7 8 Next >
    Protagonist Therapeutics Announces Positive Topline Results with JNJ-2113, the First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis
    Via ACCESSWIRE
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    Why Li Auto Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Gainers PolyMet Mining Corp. (NYSE: PLM) shares surged 144% to $1.92 after the company announced Glencore made a non-binding proposal to acquire the company for $2.11 per share. 
    Via Benzinga
    Where Protagonist Therapeutics Stands With Analysts
    Via Benzinga
    Chart Of The Day: Protagonist Therapeutics - Wide Opinions
    Via Talk Markets
    Protagonist Therapeutics Inc. (NASDAQ: PTGX) is a Stock Spotlight on 6/1
    Via Investor Brand Network
    Protagonist Therapeutics: Q1 Earnings Insights
    Via Benzinga
    AstraZeneca, ECARX Holdings And Other Big Stocks Moving Lower On Monday
    U.S. stocks traded mixed, with the Dow Jones dropping around 30 points on Monday. Here are some big stocks recording losses in today’s session. Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares... 
    Via Benzinga
    US Stocks Mixed; Dow Falls Over 50 Points
    U.S. stocks traded mixed this morning, with the Dow Jones dropping more than 50 points on Monday. Following the market opening Monday, the Dow traded down 0.19% to 34,341.91 while the NASDAQ rose 0.28%... 
    Via Benzinga
    Are (More) Big Gains Ahead for This Small Cap Biotech Stock?
    With Biomea Fusion's share price nearly halved recently, oversold conditions seem to be setting in. This could be an opportunity for small cap growth investors. 
    Via MarketBeat
    Topics Initial Public Offering
    Exposures Securities Market
    Clinical Response and Durability of Response of Rusfertide (PTG-300) in Polycythemia Vera Featured Today at EHA Press Briefing; Protagonist Therapeutics Plans a Follow-on Two-Year Extension Study to Enable Further Evaluation of the Long-Term Effects of
    Via ACCESSWIRE
    4 Analysts Have This to Say About Protagonist Therapeutics
    Via Benzinga
    Protagonist Therapeutics Touts Positive Data From Bone Marrow Disorder Study
    Via Benzinga
    Why Protagonist Therapeutics Shares Are Trading Higher Today
    Via Benzinga
    Protagonist Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at 2023 European Hematology Association (EHA) Congress
    Via ACCESSWIRE
    Protagonist Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
    Via ACCESSWIRE
    Promising Phase 1 Results: Protagonist Therapeutics and Janssen Biotech Unlock New Potential in Colitis and Inflammation Treatment
    Protagonist Therapeutics (NASDAQ: PTGX) reported data from its collaboration with Janssen Biotech Inc, a unit of Johnson & Johnson (NYSE: JNJ), on Phase 1 and preclinical studies of  
    Via Benzinga
    Protagonist, A Top 1% Biotech, Briefly Breaks Out On Psoriasis Enthusiasm
    The company is targeting psoriasis with a first-ever mechanism that could rival leaders. 
    Via Investor's Business Daily
    Why Shares of Protagonist Therapeutics Rose This Week
    The company's lead pipeline candidate is making news. 
    Via The Motley Fool
    Why Protagonist Therapeutics Shares Are Nosediving
    Protagonist Therapeutics Inc (NASDAQ: PTGX) shares are trading lower by 9.68% to $19.46 Wednesday morning after the company announced pricing of a $100 million public offering of shares of common... 
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    Protagonist Therapeutics Announces Pricing of $100 Million Public Offering of Shares of Common Stock
    Via ACCESSWIRE
    Protagonist Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
    Via ACCESSWIRE
    Protagonist Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
    Via ACCESSWIRE
    Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera
    Via ACCESSWIRE
    Top 5 Health Care Stocks That Are Ticking Portfolio Bombs
    The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
    Via Benzinga
    Why Rivian Automotive Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) jumped 99% to $1.3195 after the company announced an agreement for the distribution of an Avian Influenza A Virus real-time PCR test kit to the... 
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    Dick's Sporting Goods, WW International, Sea Limited And Other Big Stocks Moving Higher On Tuesday
    U.S. stocks traded lower, with the Dow Jones dropping around 150 points on Tuesday. Here are some big stocks recording gains in today’s session. 
    Via Benzinga
    Top 5 Health Care Stocks That May Collapse In February
    The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.